Pharmacovigilance of antiretroviral dolutegravir in the state of Paraná
The aim of this study was to investigate adverse reactions to Dolutegravir, a drug recently made available by the Unified Health System (SUS) for treating HIV infections. The frequency, severity and sex distribution of adverse reactions to Dolutegravir were identified over the first 18 months of it...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universidade Estadual de Maringá
2022-01-01
|
| Series: | Acta Scientiarum. Health Sciences |
| Subjects: | |
| Online Access: | https://periodicos.uem.br/ojs/index.php/ActaSciHealthSci/article/view/53630 |
| _version_ | 1818280703107792896 |
|---|---|
| author | Bárbara Thaís Poliselo de Sá Frederico Alves Dias Flavia Helen Correia Doroteia Aparecida Höfelmann Yanna Dantas Rattmann |
| author_facet | Bárbara Thaís Poliselo de Sá Frederico Alves Dias Flavia Helen Correia Doroteia Aparecida Höfelmann Yanna Dantas Rattmann |
| author_sort | Bárbara Thaís Poliselo de Sá |
| collection | DOAJ |
| description |
The aim of this study was to investigate adverse reactions to Dolutegravir, a drug recently made available by the Unified Health System (SUS) for treating HIV infections. The frequency, severity and sex distribution of adverse reactions to Dolutegravir were identified over the first 18 months of its availability in users in the state of Paraná. Information was obtained through the pharmacovigilance questionnaire prepared by the Ministry of Health, accessed through the Logistics Control System for Medicines (SICLOM). During the study period, dolutegravir was dispensed to 9,865 patients in the state. However, 9,207 users (93.3%) answered the pharmacovigilance questionnaire. Among them, 1.75% reported 279 adverse reactions. This population was composed mainly of male people (69.57%), in the ratio of 2.29 men for each woman, white (67.08%), aged between 20 and 29 years (26.71%), single (45.34%) and with education between 8 and 11 years of study (41.61%). Gastrointestinal (36.92%) and nervous system (14.34%) disorders were the most prevalent. 77.78% adverse reactions were considered non-serious by users. It can be concluded that dolutegravir had a low prevalence of adverse reactions in users in the state of Paraná, demonstrating to be safe for use by the population in therapy against HIV, in accordance with clinical trials
|
| first_indexed | 2024-12-12T23:53:26Z |
| format | Article |
| id | doaj.art-20c9a08a4d7c4d8fba22c17eb3867a56 |
| institution | Directory Open Access Journal |
| issn | 1679-9291 1807-8648 |
| language | English |
| last_indexed | 2024-12-12T23:53:26Z |
| publishDate | 2022-01-01 |
| publisher | Universidade Estadual de Maringá |
| record_format | Article |
| series | Acta Scientiarum. Health Sciences |
| spelling | doaj.art-20c9a08a4d7c4d8fba22c17eb3867a562022-12-22T00:06:37ZengUniversidade Estadual de MaringáActa Scientiarum. Health Sciences1679-92911807-86482022-01-0144110.4025/actascihealthsci.v44i1.53630Pharmacovigilance of antiretroviral dolutegravir in the state of ParanáBárbara Thaís Poliselo de Sá0Frederico Alves Dias1Flavia Helen Correia2Doroteia Aparecida Höfelmann3Yanna Dantas Rattmann4Universidade Federal do ParanáSecretaria de Estado da Saúde do ParanáUniversidade Federal do ParanáUniversidade Federal do ParanáUniversidade Federal do Paraná The aim of this study was to investigate adverse reactions to Dolutegravir, a drug recently made available by the Unified Health System (SUS) for treating HIV infections. The frequency, severity and sex distribution of adverse reactions to Dolutegravir were identified over the first 18 months of its availability in users in the state of Paraná. Information was obtained through the pharmacovigilance questionnaire prepared by the Ministry of Health, accessed through the Logistics Control System for Medicines (SICLOM). During the study period, dolutegravir was dispensed to 9,865 patients in the state. However, 9,207 users (93.3%) answered the pharmacovigilance questionnaire. Among them, 1.75% reported 279 adverse reactions. This population was composed mainly of male people (69.57%), in the ratio of 2.29 men for each woman, white (67.08%), aged between 20 and 29 years (26.71%), single (45.34%) and with education between 8 and 11 years of study (41.61%). Gastrointestinal (36.92%) and nervous system (14.34%) disorders were the most prevalent. 77.78% adverse reactions were considered non-serious by users. It can be concluded that dolutegravir had a low prevalence of adverse reactions in users in the state of Paraná, demonstrating to be safe for use by the population in therapy against HIV, in accordance with clinical trials https://periodicos.uem.br/ojs/index.php/ActaSciHealthSci/article/view/53630dolutegravir; HIV; Anti-retroviral agent; drug-related side effects; adverse reactions. |
| spellingShingle | Bárbara Thaís Poliselo de Sá Frederico Alves Dias Flavia Helen Correia Doroteia Aparecida Höfelmann Yanna Dantas Rattmann Pharmacovigilance of antiretroviral dolutegravir in the state of Paraná Acta Scientiarum. Health Sciences dolutegravir; HIV; Anti-retroviral agent; drug-related side effects; adverse reactions. |
| title | Pharmacovigilance of antiretroviral dolutegravir in the state of Paraná |
| title_full | Pharmacovigilance of antiretroviral dolutegravir in the state of Paraná |
| title_fullStr | Pharmacovigilance of antiretroviral dolutegravir in the state of Paraná |
| title_full_unstemmed | Pharmacovigilance of antiretroviral dolutegravir in the state of Paraná |
| title_short | Pharmacovigilance of antiretroviral dolutegravir in the state of Paraná |
| title_sort | pharmacovigilance of antiretroviral dolutegravir in the state of parana |
| topic | dolutegravir; HIV; Anti-retroviral agent; drug-related side effects; adverse reactions. |
| url | https://periodicos.uem.br/ojs/index.php/ActaSciHealthSci/article/view/53630 |
| work_keys_str_mv | AT barbarathaispoliselodesa pharmacovigilanceofantiretroviraldolutegravirinthestateofparana AT fredericoalvesdias pharmacovigilanceofantiretroviraldolutegravirinthestateofparana AT flaviahelencorreia pharmacovigilanceofantiretroviraldolutegravirinthestateofparana AT doroteiaaparecidahofelmann pharmacovigilanceofantiretroviraldolutegravirinthestateofparana AT yannadantasrattmann pharmacovigilanceofantiretroviraldolutegravirinthestateofparana |